See more : Inspirit Energy Holdings Plc (INSP.L) Income Statement Analysis – Financial Results
Complete financial analysis of Eagle Pharmaceuticals, Inc. (EGRX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Eagle Pharmaceuticals, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Universal Incorporation (1325.TW) Income Statement Analysis – Financial Results
- Quantum Solar Power Corp. (QSPW) Income Statement Analysis – Financial Results
- Ayvens (AYV.PA) Income Statement Analysis – Financial Results
- Tongtai Machine & Tool Co., Ltd. (4526.TW) Income Statement Analysis – Financial Results
- Old Market Capital Corporation (OMCC) Income Statement Analysis – Financial Results
Eagle Pharmaceuticals, Inc. (EGRX)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.eagleus.com
About Eagle Pharmaceuticals, Inc.
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 316.61M | 171.55M | 187.80M | 195.89M | 213.31M | 236.71M | 189.48M | 66.23M | 19.10M | 13.68M | 2.54M |
| Cost of Revenue | 94.94M | 42.18M | 45.47M | 60.90M | 61.92M | 57.19M | 55.31M | 15.65M | 11.71M | 7.38M | 3.17M |
| Gross Profit | 221.67M | 129.37M | 142.34M | 135.00M | 151.40M | 179.52M | 134.18M | 50.58M | 7.39M | 6.30M | -627.00K |
| Gross Profit Ratio | 70.01% | 75.41% | 75.79% | 68.91% | 70.97% | 75.84% | 70.81% | 76.37% | 38.67% | 46.04% | -24.69% |
| Research & Development | 34.09M | 51.28M | 30.79M | 36.81M | 44.42M | 32.61M | 30.26M | 27.86M | 16.82M | 9.80M | 12.81M |
| General & Administrative | 98.13M | 66.82M | 75.90M | 73.97M | 57.21M | 73.07M | 37.53M | 15.41M | 5.02M | 0.00 | 0.00 |
| Selling & Marketing | 8.50M | 8.50M | 2.70M | 2.40M | 3.30M | -1.65M | 14.78M | 4.75M | 4.30M | 0.00 | 0.00 |
| SG&A | 106.63M | 75.32M | 78.60M | 76.37M | 60.51M | 71.42M | 52.31M | 20.17M | 9.33M | 4.96M | 6.40M |
| Other Expenses | 0.00 | -6.24M | -8.26M | 700.00K | 52.23M | 35.22M | 32.57M | 0.00 | 35.00K | 3.20K | 12.00K |
| Operating Expenses | 140.71M | 126.60M | 109.38M | 113.18M | 104.93M | 104.02M | 82.58M | 48.02M | 26.14M | 14.75M | 19.20M |
| Cost & Expenses | 235.65M | 168.78M | 154.85M | 174.08M | 166.84M | 161.21M | 137.88M | 63.67M | 37.86M | 22.13M | 22.37M |
| Interest Income | 271.00K | 560.00K | 562.00K | 2.17M | 158.00K | 91.00K | 84.00K | 25.00K | 31.00K | 3.21K | 34.00K |
| Interest Expense | 4.05M | 1.64M | 2.58M | 2.69M | 2.74M | 1.14M | 8.00K | 11.00K | 8.00K | 1.40M | 309.00K |
| Depreciation & Amortization | 12.02M | 4.81M | 4.77M | 4.65M | 3.67M | 3.75M | 1.59M | 112.00K | 104.00K | 134.99K | 240.00K |
| EBITDA | 77.50M | 2.77M | 30.02M | 28.18M | 40.44M | 77.83M | 55.02M | 2.70M | -18.76M | -8.41M | -19.62M |
| EBITDA Ratio | 24.48% | 0.49% | 15.98% | 14.98% | 23.58% | 33.52% | 27.28% | 3.90% | -97.86% | -61.48% | -770.54% |
| Operating Income | 80.96M | -2.91M | 25.25M | 21.82M | 36.62M | 73.99M | 53.35M | 2.56M | -18.76M | -8.46M | -19.83M |
| Operating Income Ratio | 25.57% | -1.70% | 13.45% | 11.14% | 17.17% | 31.26% | 28.16% | 3.87% | -98.21% | -61.81% | -781.06% |
| Total Other Income/Expenses | -19.53M | -7.32M | -10.28M | 183.00K | -2.58M | -1.05M | 76.00K | 14.00K | -515.00K | 1.51M | -333.00K |
| Income Before Tax | 61.43M | -4.55M | 22.68M | 22.00M | 34.04M | 72.95M | 53.43M | 2.57M | -19.27M | -6.95M | -20.16M |
| Income Before Tax Ratio | 19.40% | -2.65% | 12.07% | 11.23% | 15.96% | 30.82% | 28.20% | 3.89% | -100.91% | -50.79% | -794.17% |
| Income Tax Expense | 25.79M | 4.08M | 10.69M | 7.69M | 2.14M | 21.00M | -28.03M | 3.00K | -1.30M | -898.70K | -781.00K |
| Net Income | 35.64M | -8.63M | 11.99M | 14.31M | 31.90M | 51.94M | 81.45M | 2.57M | -17.98M | -6.05M | -19.38M |
| Net Income Ratio | 11.26% | -5.03% | 6.38% | 7.31% | 14.96% | 21.94% | 42.99% | 3.88% | -94.13% | -44.22% | -763.41% |
| EPS | 2.76 | -0.66 | 0.89 | 1.04 | 2.16 | 3.44 | 5.24 | 0.17 | -1.81 | -0.57 | -1.83 |
| EPS Diluted | 2.73 | -0.66 | 0.87 | 1.01 | 2.09 | 3.27 | 4.96 | 0.16 | -1.81 | -0.57 | -1.83 |
| Weighted Avg Shares Out | 12.93M | 13.05M | 13.48M | 13.75M | 14.77M | 15.10M | 15.53M | 15.25M | 9.96M | 10.57M | 10.57M |
| Weighted Avg Shares Out (Dil) | 13.07M | 13.05M | 13.77M | 14.14M | 15.28M | 15.91M | 16.43M | 16.25M | 9.96M | 10.57M | 10.57M |
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Eagle Pharmaceuticals, Inc.(EGRX) Investors of a Class Action Lawsuit and Upcoming Deadline
DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors in Eagle Pharmaceuticals, Inc. - EGRX
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Eagle Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 9, 2024 - (NASDAQ: EGRX)
EAGLE PHARMACEUTICALS INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Eagle Pharmaceuticals To Contact Him Directly To Discuss Their Options
EGRX Investors Have Opportunity to Lead Eagle Pharmaceuticals, Inc. Securities Fraud Lawsuit
DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
SHAREHOLDER ALERT: The Law Offices of Vincent Wong Remind Eagle Pharmaceuticals Investors of a Lead Plaintiff Deadline of February 9, 2024
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
Source: https://incomestatements.info
Category: Stock Reports